PCSK9 Inhibitors in the Progression of Aortic Stenosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

140 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-06-01

Study Completion Date

2020-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigators plan evaluate whether PCSK9 inhibitors, a medication that can lower lipoprotein(a) and control dyslipidemia, can inhibit the progression of aortic stenosis, through a randomized controlled trial.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PCSK9 Inhibitors in the Treatment of Calcific Aortic Stenosis

NCT07256197

Aortic Stenosis, Calcific

NOT_YET_RECRUITING PHASE3

Effect of PCSK9 Inhibitors on Calcific Aortic Valve Stenosis

NCT04968509

Aortic Stenosis

RECRUITING PHASE3

A Multicenter, Prospective, Randomized Controlled Trial to Evaluate the Efficacy of PCSK-9 Inhibitors in Delaying the Progression of Calcified Aortic Valve Disease

NCT06996223

Aortic Stenosis PCSK9 Inhibitor Calcified Aortic Valve Disease

NOT_YET_RECRUITING EARLY_PHASE1

Clinical Trial of PCSK9 Inhibitor and Statin Treatment for Carotid Artery Stenosis

NCT07036991

Carotid Artery Stenosis

NOT_YET_RECRUITING PHASE4

Acute Myocardial Infarction and Unstable Angina Patients With PCSK9 Inhibitor Usage Study

NCT04730648

Lipid Metabolism Cardiovascular Diseases

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Aortic valve disease is the most common form of heart valve disease and is a major burden to society. Aortic valve disease is also expected to become more prevalent with the aging. Among aortic diseases, 'aortic stenosis (AS)', which is a narrowing of the aortic valve, and leads to symptoms of heart failure and sometimes death.

For treatment of AS, the valve in replaced in a surgical to percutaneous method. Regardless of the method, valve replacement has its potential costs and complications that is an important issue that needs to be solved. Therefore, controlling the progression of AS and increasing the efficacy of medical therapy before valvular replacement is needed, is an important medico-social problem.

Regarding the pathophysiology of AS, an elevation of lipoprotein(a) and dyslipidemia have been reported to be associated with the progression of cardiovascular calcification.

PCSK9 inhibitors, which is a medication that can control both lipoprotein(a) and dyslipidemia may be a effective medication to control the progression of AS.

Therefore, investigators will perform a randomized control trial, to compare the effect of PCSK9 inhibitors vs. placebo in its influence to AS progression.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aortic Valve Stenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Prospective, Double blind, Multi-center, Randomized clinical trial

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PCSK9 inhibitor

Patients will receive bi-weekly PCSK9 inhibitor .

Group Type ACTIVE_COMPARATOR

PCSK9 Inhibitor [EPC]

Intervention Type DRUG

Patients will receive PCSK9 inhibitor by a biweekly injection

Placebo

Patients will receive bi-weekly placebo.

Group Type PLACEBO_COMPARATOR

Placebos

Intervention Type DRUG

Patients will receive Placebo by a biweekly injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PCSK9 Inhibitor [EPC]

Patients will receive PCSK9 inhibitor by a biweekly injection

Intervention Type DRUG

Placebos

Patients will receive Placebo by a biweekly injection

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The patient agrees to participate in this study by signing the informed consent form. Alternatively, a legally authorized patient representative may agree to the patient's participation in this study and sign the informed consent form.
2. The patient has a working diagnosis of aortic stenosis (mild to moderate), and has fair treatment compliance.

Exclusion Criteria

1. Age under 19 years old
2. Hypersensitivity to PCSK9 inhibitor
3. LDL cholesterol \< 70mg/dL at baseline
4. Poor treatement compliance (The patient will need to visit the out-patient clinic every 2-weeks for medication)
5. Positive pregnancy test or is known to be pregnant
6. Any other reason the investigator deems the subject to be unsuitable for the study (e.g., Active malignant tumor, Any life-threatening condition with life expectancy less than 6months, etc.)
7. Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the investigator, would preclude safe completion of the study

Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No